Single-nucleotide polymorphisms in CCL2 gene are not associated with susceptibility to systemic sclerosis

Journal of Rheumatology

Volumn 35, Issue 5, 2008, Pages 839-844

  Carulli, Maria Teresa ^a   Spagnolo, Paolo ^b   Fonseca, Carmen ^a   Welsh, Kenneth I ^b   DuBois, Roland M ^b   Black, Carol M ^a   Denton, Christopher P ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^b NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

Author keywords

CCL2; Chemokines; Genetic polymorphisms; Scleroderma; Single nucleotide polymorphism; Systemic sclerosis

Indexed keywords

MONOCYTE CHEMOTACTIC PROTEIN 1;

3' UNTRANSLATED REGION; ADULT; ALLELE; ARTICLE; CAUCASIAN; COHORT ANALYSIS; CONTROLLED STUDY; EXON; FEMALE; GENE SEQUENCE; GENETIC ASSOCIATION; GENETIC PREDISPOSITION; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE; HUMAN; HYPOTHESIS; MAJOR CLINICAL STUDY; MALE; PHENOTYPE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMOTER REGION; SINGLE NUCLEOTIDE POLYMORPHISM; SYSTEMIC SCLEROSIS;

CASE-CONTROL STUDIES; CHEMOKINE CCL2; CHROMOSOME MAPPING; COHORT STUDIES; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HAPLOTYPES; HUMANS; MALE; MIDDLE AGED; PHENOTYPE; POLYMORPHISM, SINGLE NUCLEOTIDE; SCLERODERMA, SYSTEMIC;

EID: 44349165810     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. LeRoy EC, Black C, Fleischmajer R, et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 1988;15:202-5.
2. Bunn, CC, Black CM. Systemic sclerosis: an autoantibody mosaic. Clin Exp Immunol 1999;117:207-8.
3. LeRoy, EC, Trojanowska M, Smith EA. The pathogenesis of scleroderma (systemic sclerosis, SSc). Clin Exp Rheumatol 1991;9:173-7.
4. Fagundus DM, LeRoy EC. Cytokines and systemic sclerosis. Clin Dermatol 1994;12:407-17.
5. Postlethwaite AE. Connective tissue metabolism including cytokines in scleroderma. Curr Opin Rheumatol 1995;7:535-40.
6. Steen VD. Occupational scleroderma. Curr Opin Rheumatol 1999;11:490-4.
7. Mayes MD. Epidemiologic studies of environmental agents and systemic autoimmune diseases. Environ Health Perspect 1999;107 Suppl:743-8.
8. Baggiolini M. Chemokines and leukocyte traffic. Nature 1998;392:565-8.
9. Charo IF, Taubman MB. Chemokines in the pathogenesis of vascular disease. Circ Res 2004;95:858-66.
10. Rossi D, Zlotnik A. The biology of chemokines and their receptors. Annu Rev Immunol 2000;18:217-42.
11. Leonard EJ, Yoshimura T. Human monocyte chemoattractant protein-1 (MCP-1). Immunol Today 1990;11:97-101.
12. Denton CP, Shi-Wen X, Sutton A, Abraham DJ, Black CM, Pearson JD. Scleroderma fibroblasts promote migration of mononuclear leucocytes across endothelial cell monolayers. Clin Exp Immunol 1998;114:293-300.
13. Galindo M, Santiago B, Rivero M, Rullas J, Alcami J, Pablos JL. Chemokine expression by systemic sclerosis fibroblasts: abnormal regulation of monocyte chemoattractant protein 1 expression. Arthritis Rheum 2001;44:1382-6.
14. Yamamoto T, Eckes B, Hartmann K, Krieg T. Expression of monocyte chemoattractant protein-1 in the lesional skin of systemic sclerosis. J Dermatol Sci 2001;26:133-9.
15. Distler O, Pap T, Kowal-Bielecka O, et al. Overexpression of monocyte chemoattractant protein 1 in systemic sclerosis: role of platelet-derived growth factor and effects on monocyte Chemotaxis and collagen synthesis. Arthritis Rheum 2001;44:2665-78.
16. Carulli MT, Ong VH, Ponticos M, et al. Chemokine receptor CCR2 expression by systemic sclerosis fibroblasts: evidence for autocrine regulation of myofibroblast differentiation. Arthritis Rheum 2005;52:3772-82.
17. Atamas SP, White B. The role of chemokines in the pathogenesis of scleroderma. Curr Opin Rheumatol 2003;15:772-7.
18. Rovin BH, Lu L, Saxena R. A novel polymorphism in the MCP-1 gene regulatory region that influences MCP-1 expression. Biochem Biophys Res Commun 1999;259:344-8.
19. Szalai C, Duba J, Prohaszka Z, et al. Involvement of polymorphisms in the chemokine system in the susceptibility for coronary artery disease (CAD). Coincidence of elevated Lp(a) and MCP-1 -2518 G/G genotype in CAD patients. Atherosclerosis 2001;158:233-9.
20. Szalai C, Kozma GT, Nagy A, et al. Polymorphism in the gene regulatory region of MCP-1 is associated with asthma susceptibility and severity. J Allergy Clin Immunol 2001;108:375-81.
21. Muhlbauer M, Bosserhoff AK, Hartmann A, et al. A novel MCP-1 gene polymorphism is associated with hepatic MCP-1 expression and severity of HCV-related liver disease. Gastroenterology 2003;125:1085-93.
22. Herfarth H, Goke M, Hellerbrand C, et al. Polymorphism of monocyte chemoattractant protein 1 in Crohn's disease. Int J Colorectal Dis 2003;18:401-5.
23. Karrer S, Bosserhoff AK, Weiderer P, et al. The -2518 promotor polymorphism in the MCP-1 gene is associated with systemic sclerosis. J Invest Dermatol 2005;124:92-8.
24. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Arthritis Rheum 1980;23:581-90.
25. Valentini G, Bencivelli W, Bombardieri S, et al. European Scleroderma Study Group to define disease activity criteria for systemic sclerosis. III. Assessment of the construct validity of the preliminary activity criteria. Ann Rheum Dis 2003;62:901-3.
26. Bunce M, O'Neill CM, Barnardo MC, et al. Phototyping: comprehensive DNA typing for HLA-A, B, C, DRB1, DRB3, DRB4, DRB5 and DQB1 by PCR with 144 primer mixes utilizing sequence-specific primers (PCR-SSP). Tissue Antigens 1995;46:355-67.
27. Stephens M, Smith NJ, Donnelly P. A new statistical method for haplotype reconstruction from population data. Am J Hum Genet 2001;68:978-89.
28. Gharaee-Kermani M, Denholm EM, Phan SH. Costimulation of fibroblast collagen and transforming growth factor beta-1 gene expression by monocyte chemoattractant protein-1 via specific receptors. J Biol Chem 1996;271:17779-84.
29. Luzina IG, Atamas SP, Wise R, Wigley FM, Xiao HQ, White B. Gene expression in bronchoalveolar lavage cells from scleroderma patients. Am J Respir Cell Mol Biol 2002;26:549-57.
30. Hasegawa M, Sato S, Takehara K. Augmented production of chemokines (monocyte chemotactic protein-1 (MCP-1), macrophage inflammatory protein-1 alpha (MIP-1 alpha) and MIP-1 beta) in patients with systemic sclerosis: MCP-1 and MIP-1 alpha may be involved in the development of pulmonary fibrosis. Clin Exp Immunol 1999;117:159-65.
31. Aguilar F, Gonzalez-Escribano MF, Sanchez-Roman J, Nunez-Roldan A. MCP-1 promoter polymorphism in Spanish patients with systemic lupus erythematosus. Tissue Antigens 2001;58:335-8.
32. Kruger B, Schroppel B, Ashkan R, et al. A monocyte chemoattractant protein-1 (MCP-1) polymorphism and outcome after renal transplantation. J Am Soc Nephrol 2002;13:2585-9.